Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation

Kidney International

Volumn 85, Issue 2, 2014, Pages 425-430

  Ashimine, Satoshi ^a   Watarai, Yoshihiko ^a   Yamamoto, Takayuki ^a   Hiramitsu, Takahisa ^a   Tsujita, Makoto ^a   Nanmoku, Koji ^a   Goto, Norihiko ^a   Takeda, Asami ^a   Katayama, Akio ^b   Uchida, Kazuharu ^c   Kobayashi, Takaaki ^d  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b Masuko Memorial Hospital   (Japan)

^c AICHI MEDICAL UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

desensitization; HLA antibodies; renal transplantation; rituximab

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; EVEROLIMUS; HLA ANTIBODY; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD GROUP ABO SYSTEM; CHILD; CHRONIC GRAFT REJECTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENECTOMY; SURVIVAL TIME;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL MARKERS; BLOOD GROUP INCOMPATIBILITY; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; SPLENECTOMY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893296695     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.291     Document Type: Article

References (45)

1. Terasaki P, Mizutani K. Antibody mediated rejection: Update 2006. Clin J Am Soc Nephrol 2006; 1: 400-403
2. Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: A review. J Transplant 2012; 2012: 193724
3. Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int 2013; 23: 563-575
4. Kohei N, Hirai T, Omoto K et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012; 12: 469-476
5. Jordan SC, Kahwaji J, Toyoda M et al. B-cell immunotherapeutics: Emerging roles in solid organ transplantation. Curr Opin Organ Transplant 2011; 16: 416-424
6. Morath C, Opelz G, Zeier M et al. Prevention of antibody-mediated kidney transplant rejection. Transpl Int 2012; 25: 633-645
7. Loupy A, Suberbielle-Boissel C, Zuber J et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplantation 2010; 89: 1403-1410
8. Tyden G, Ekberg H, Tufveson G et al. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: A 3-year follow-up. Transplantation 2012; 94: E21-e22
9. Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: Therapeutic options and their experimental rationale. Transpl Int 2012; 25: 623-632
10. Kahwaji J, Sinha A, Toyoda M et al. Infectious complications in kidneytransplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin J Am Soc Nephrol 2011; 6: 2894-2900
11. Kamar N, Milioto O, Puissant-Lubrano B et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-Transplant patients. Am J Transplant 2010; 10: 89-98
12. Habicht A, Broker V, Blume C et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients-A single centre experience. Nephrol Dial Transplant 2011; 26: 4124-4131
13. Tyden G, Genberg H, Tollemar J et al. A randomized, double blind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009; 87: 1325-1329
14. Dzabic M, Rahbar A, Yaiw KC et al. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011; 53: 969-976
15. Segev DL, Simpkins CE, Warren DS et al. ABO incompatible high-Titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5: 2570-2575
16. Flint SM, Walker RG, Hogan C et al. Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression. Am J Transplant 2011; 11: 1016-1024
17. Genberg H, Hansson A, Wernerson A et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428
18. Toki D, Ishida H, Horita S et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22: 447-454
19. Oketani M, Ido A, Uto H et al. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2013; 42: 627-636
20. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013; 43: 113-121
21. Kasiske BL, Guijarro C, Massy ZA et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-165
22. Belliere J, Rostaing L, Guilbeau-Frugier C et al. Low-versus high-dose rituximab for antibody-mediated rejection after kidney transplantation. Transpl Int 2012; 26: E12-e14
23. Tait BD. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009; 21: 573-577
24. Leffell MS, Zachary AA. Anti-Allograft antibodies: Some are harmful, some can be overcome, and some may be beneficial. Discov Med 2010; 9: 478-484
25. Ponticelli C. Humoral antibodies in organ transplantation: Angels or demons? Am J Transplant 2010; 10: 1332
26. Cai J, Terasaki PI, Mao Q et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947-2954
27. Mao Q, Terasaki PI, Cai J et al. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation 2007; 83: 54-61
28. Lachmann N, Terasaki PI, Budde K et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505-1513
29. Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804-2812
30. Kobayashi T, Maruya E, Niwa M et al. Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation. Hum Immunol 2011; 72: 11-17
31. Ntokou IS, Iniotaki AG, Kontou EN et al. Long-Term follow up for anti-HLA donor specific antibodies postrenal transplantation: High immunogenicity of HLA class II graft molecules. Transpl Int 2011; 24: 1084-1093
32. Duquesnoy RJ, Awadalla Y, Lomago J et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. Transpl Immunol 2008; 18: 352-360
33. Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 2010; 22: 105-109
34. Miettinen J, Perasaari J, Lauronen J et al. Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol 2012; 27: 1011-1019
35. Tambur AR, Leventhal JR, Friedewald JJ et al. The complexity of human leukocyte antigen (HLA)-DQ antibodies and its effect on virtual crossmatching. Transplantation 2010; 90: 1117-1124
36. Willicombe M, Brookes P, Sergeant R et al. De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172-177
37. DeVos JM, Gaber AO, Knight RJ et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598-604
38. Iwasaki K, Miwa Y, Ogawa H et al. Comparative study on signal transduction in endothelial cells after anti-A/b and human leukocyte antigen antibody reaction: Implication of accommodation. Transplantation 2012; 93: 390-397
39. Narayanan K, Jendrisak MD, Phelan DL et al. HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway. Transpl Immunol 2006; 15: 187-197
40. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459-2465
41. Wiebe C, Gibson IW, Blydt-Hansen TD et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167
42. Sellares J, de Freitas DG, Mengel M et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2011; 12: 388-399
43. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: Case series and comprehensive review of the literature. Medicine (Baltimore) 2010; 89: 308-318
44. Hadjinicolaou AV, Nisar MK, Parfrey H et al. Non-infectious pulmonary toxicity of rituximab: A systematic review. Rheumatology (Oxford) 2012; 51: 653-662
45. Sis B, Mengel M, Haas M et al. Banff 09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471